Future Fertility, a Toronto-based provider of AI tools for oocyte quality assessment, has raised $4.1M in Series A funding led by M Ventures and Whitecap Venture Partners. The platform analyzes microscope images of eggs to predict blastocyst development and live birth potential more accurately than human embryologists. The capital will support APAC expansion, US market entry via FDA 510(k) clearance, and broader AI platform development.
IVF AI Funding Accelerates Globally
The round comes amid rising investment in AI-driven IVF tools. Conceivable Life Sciences raised $50M Series A in September 2024 for IVF lab automation. Future Fertility's oocyte-focused AI addresses pre-fertilization gaps that embryo-centric rivals overlook.
Subjective Egg Assessment Limits IVF
Embryologists rely on subjective visual grading of oocytes, leading to inconsistent predictions of IVF success. Current methods fail to quantify egg quality beyond age and count, leaving 50% of patients unaware of their odds per research cited in coverage. This hampers personalized counseling in IVF, egg freezing, and donor programs.
AI Outperforms Humans on Egg Quality
Future Fertility's tools—VIOLET™ for egg freezing, MAGENTA™ for IVF-ICSI, and ROSE™ for donor eggs—use AI trained on 650,000+ images from 15+ countries. The models show 18% higher accuracy than 50 embryologists in blastocyst prediction and 100% repeatability versus humans' 81% per company research.
As CEO Christy Prada noted:
"Every patient deserves objective data… This funding means we can bring that clarity to more patients."
Non-Invasive Insights Transform Counseling
Unlike competitors focused on post-fertilization embryo analysis like Life Whisperer or AiVF, Future Fertility enables upfront decisions. Deployed in 300+ clinics across 35+ countries, the platform integrates with lab workflows and offers patient-facing reports via MyFutureFertility.
Merck CVC Validates Fertility AI
M Ventures, the strategic arm of Merck KGaA, brings biotech expertise from exits like Progyny's IPO. Whitecap adds Canadian healthtech conviction with portfolio wins like Real Matters' IPO. Participation from Sandpiper Ventures, Gaingels, and Jolt VC signals diversity and momentum in femtech.
As Oliver Hardick of M Ventures stated:
"Future Fertility is addressing a critical unmet need… potential to improve decision-making for clinicians."
IVF Market Grows Amid AI Adoption
The global IVF market stood at $25.3B in 2023 and projects to reach $37.4B by 2030 at 5.54% CAGR per Grand View Research. Trends like egg freezing and insurance expansions drive demand for objective tools.
Founder-Clinician Builds Credible AI
Co-founder Dan Nayot, a board-certified reproductive endocrinologist with a Harvard MSc in epidemiology, pairs clinical insight with math expertise. CTO Alex Krivoi leads AI development with peer-reviewed publications. Executive Chairman Rene Bharti founded public telehealth firm ARHT Media from personal IVF experience.
US APAC Expansion Targets Growth
Future Fertility plans FDA 510(k) for US entry, APAC scaling via partners like Japan's Kato Ladies Clinic, and US sales hires. Recent ISO 13485 and MDSAP certifications enable global medical device sales. Insurance coverage from Sun Life and Manulife in Canada boosts reimbursement.